Cagrilintide 5mg

Cagrilintide

Primary Function: Appetite suppression, weight loss, metabolic regulation
Research Use: Obesity models, GLP-1/Amylin synergy, energy balance studies
Molecular Formula: C271H411N75O83S
CAS Number: 2134203-73-1
Synonyms: NN9838, AM833, Long-acting amylin analog

Description:
Cagrilintide is a long-acting amylin analog developed to mimic and extend the effects of the natural hormone amylin, which is co-secreted with insulin by pancreatic β-cells. It binds to amylin receptors and modulates appetite, satiety, and gastric emptying. In research, Cagrilintide has shown synergistic effects with GLP-1 receptor agonists (such as Semaglutide) in promoting significant and sustained weight loss, making it a promising candidate in obesity and metabolic disorder studies.

Mechanism of Action:

• Binds to amylin receptors (AMYRs) in the brain
• Delays gastric emptying, promoting early satiety
• Reduces food intake and modulates reward-based eating
• Works synergistically with GLP-1 analogs for enhanced metabolic effects

Key Research Areas:

• Obesity and weight management
• Appetite regulation and food intake behavior
• Combination therapy with GLP-1 agonists (e.g., Semaglutide, Tirzepatide)
• Insulin resistance and metabolic syndrome

History of Discovery:
Cagrilintide (NN9838) was developed by Novo Nordisk as a once-weekly injectable amylin receptor agonist, designed to overcome the limitations of native amylin’s short half-life. Its clinical development was geared toward co-administration with GLP-1 analogs, enabling dual hormonal regulation of appetite and metabolism in obesity research.

Case Studies:

1. Synergistic Weight Loss with Semaglutide (2021, Lancet): Co-administration of Cagrilintide and Semaglutide resulted in over 17% body weight reduction at 20 weeks vs. 9% with Semaglutide alone. [Lancet. 2021;397(10288):1736–1748.]
2. Appetite Reduction and Satiety Increase (2020, Diabetes Obes Metab): Participants reported reduced hunger scores and delayed gastric emptying following weekly doses of Cagrilintide. [Diabetes Obes Metab. 2020;22(10):1701–1710.]
3. Safety and Tolerability (Phase 2 Trials): Well tolerated at various dose levels with mild GI symptoms being the most common side effect. No major hypoglycemic events reported.

Packaging Information:

• Form: Lyophilized powder or solution
• Purity: ≥ 99%
• Storage: Store at -20°C in a dry, dark environment
• For research use only. Not for human or veterinary use.

.